Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 3/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL818239 | 0.84 | HTR6 (0.49) | SLC6A4TSHRHTR6 | |
| SCHEMBL823067 | 0.84 | HTR6 (0.49) | SLC6A4TSHRHTR6 | |
| SCHEMBL12405713 | 0.81 | XIAP (0.40) | HTR2A | |
| SCHEMBL375087 | 0.79 | GPR84 (0.52) | GPR84SLC6A4HTR2AHTR1AMAPK1 | |
| SCHEMBL820506 | 0.79 | GPR84 (0.52) | GPR84SLC6A4HTR2AHTR1AMAPK1 | |
| SCHEMBL820539 | 0.79 | HTR2A (0.35) | HTR2AMAPK1 | |
| SCHEMBL818116 | 0.79 | HTR2A (0.35) | HTR2AMAPK1 | |
| SCHEMBL820684 | 0.74 | MTNR1A (0.48) | GPR84SLC6A4HTR2AHTR1AMTNR1A | |
| SCHEMBL818489 | 0.74 | MTNR1A (0.48) | GPR84SLC6A4HTR2AHTR1AMTNR1A | |
| SCHEMBL375340 | 0.74 | GPR84 (0.37) | GPR84SLC6A4HTR2AHTR1AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049563-B1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARM CORP (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-7985735-B2 | mimetics of the activity of the N-terminal portion of Smac/tertiary binding structure to IAPs, can be combined with chemotherapeutic agents like topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds; increased cell permeability, water solubility; antitumor agents | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985735-B2 | mimetics of the activity of the N-terminal portion of Smac/tertiary binding structure to IAPs, can be combined with chemotherapeutic agents like topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds; increased cell permeability, water solubility; antitumor agents | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| WO-2009094287-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICAL CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2008014263-A2 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | BIRC2, BIRC7, BIRC8 | GPR84 3704/4885SLC6A4 4756/4885HTR2A 3777/4885 |
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | GPR84 3290/4885SLC6A4 4770/4885HTR2A 4844/4885 |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | BIRC2, BIRC7, BIRC8 | GPR84 2656/4885SLC6A4 4684/4885HTR2A 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.